Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.67 |
| ▸ | CA2 | P00918 | 1/20 | 0.67 |
| ▸ | P2RX1 | P51575 | 6/20 | 0.55 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.55 |
| ▸ | TMPRSS4 | Q9NRS4 | 3/20 | 0.53 |
| ▸ | P2RX4 | Q99571 | 3/20 | 0.53 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2956454 | 0.83 | CA1 (0.50) | CA1CA2P2RX1KCNMA1TMPRSS4 | |
| SCHEMBL6966672 | 0.82 | CA1 (0.72) | CA1CA2P2RX1KCNMA1TMPRSS4 | |
| SCHEMBL9586276 | 0.80 | ALDH1A1 (0.65) | CA1CA2MAPTHSD17B10LMNA | |
| 5-Chlorosalicylic Acid SCHEMBL130605 | 0.80 | CA1 (1.00) | CA1CA2P2RX1KCNMA1TMPRSS4 | |
| SCHEMBL4955043 | 0.80 | CA1 (0.69) | CA1CA2P2RX1KCNMA1TMPRSS4 | |
| SCHEMBL29769239 | 0.80 | CA1 (0.69) | CA1CA2P2RX1KCNMA1TMPRSS4 | |
| 5-Chlorosalicylic Acid SCHEMBL29499764 | 0.80 | CA1 (1.00) | CA1CA2P2RX1KCNMA1TMPRSS4 | |
| SCHEMBL6153483 | 0.78 | CA1 (0.67) | CA1CA2P2RX1KCNMA1TMPRSS4 | |
| SCHEMBL218964 | 0.78 | CA1 (0.67) | CA1CA2P2RX1KCNMA1TMPRSS4 | |
| 5-Chlorosalicylic Acid SCHEMBL6855770 | 0.78 | CA1 (0.96) | CA1CA2P2RX1KCNMA1TMPRSS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10399986-B2 | Inhibitors of leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180127424-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELLTAXIS, LLC | 2018-05-10 | — | — | US | disclosed |
| US-20050119237-A1 | Non-malignant disease treatment with Ras antagonists | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. (IL) | 2005-06-02 | — | — | US | disclosed |
| EP-1187605-A4 | NON-MALIGNANT DISEASE TREATMENT WITH RAS ANTAGONISTS | THYREOS CORP (US) | 2004-05-26 | — | — | EP | disclosed |
| US-6462086-B1 | SUCH AS FARNESYLTHIOSALICYLIC ACID; INHIBITING PROLIFERATION OF T-CELLS; DIABETES, LUPUS, MULTIPLE SCLEROSIS; GRAFT REJECTION INDUCED BY FOREIGN ANTIGENS; CIRRHOSIS, RESTENOSIS | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH AND INDUSTRIAL DEVELOPMENT LTD. (IL) | 2002-10-08 | — | — | US | disclosed |
| EP-1187605-A1 | NON-MALIGNANT DISEASE TREATMENT WITH RAS ANTAGONISTS | Thyreos Corporation (US) | 2002-03-20 | — | — | EP | disclosed |
| WO-2000078303-A1 | NON-MALIGNANT DISEASE TREATMENT WITH RAS ANTAGONISTS | THYREOS CORPORATION (US) | 2000-12-28 | — | — | WO | disclosed |
| US-5766556-A | SUITABLE ENVIRONMENT FOR SIMULTANEOUS SYNTHESIS OF ORGANIC COMPOUNDS, INORGANIC COMPOUNDS AND ORGANOMETALLIC COMPOUNDS | WARNER-LAMBERT COMPANY (US) | 1998-06-16 | — | — | US | disclosed |
| US-5714127-A | RESERVOIR RACKS WITH REACTION WELLS; GAS DISPERSION TUBES CONTAINING FILTERS; HOLDER BLOCK WITH APERTURES; MANIFOLD | WARNER-LAMBERT COMPANY (US) | 1998-02-03 | — | — | US | disclosed |
| US-5702672-A | REACTION TUBE COMPRISING GAS DISPERSION TUBE HAVING GROUNG GLASS JOINT SECTION | WARNER-LAMBERT COMPANY (US) | 1997-12-30 | — | — | US | disclosed |
| WO-1996030393-A1 | A METHOD FOR THE SYNTHESIS OF MIXTURES OF COMPOUNDS | WARNER-LAMBERT COMPANY (US) | 1996-10-03 | — | — | WO | disclosed |
| EP-0663856-A1 | APPARATUS AND METHOD FOR MULTIPLE SIMULTANEOUS SYNTHESIS | WARNER-LAMBERT COMPANY (US) | 1995-07-26 | — | — | EP | disclosed |
| WO-1994008711-A1 | APPARATUS AND METHOD FOR MULTIPLE SIMULTANEOUS SYNTHESIS | WARNER-LAMBERT COMPANY (US) | 1994-04-28 | — | — | WO | disclosed |
| CN-1007153-B | PREPN. OF BENZOTHIOPHENES AND BENZOFURANS HAVING ANTIALLERGY ACTIVITY | WARNER LAMBERT CO (US) | 1990-03-14 | — | — | CN | disclosed |
| US-4663344-A | ANTIPYRETICS, ANTIARTHRITIC AGENTS | MERCK & CO., INC. (US) | 1987-05-05 | — | — | US | disclosed |
| CN-85109587-A | Have the new benzothiophene kind of antiallergic activity and the preparation method of benzofuran compounds | — | 1986-12-17 | — | — | CN | disclosed |
| EP-0187487-A1 | Benzothiophenes and benzofurans having antiallergic activity | WARNER-LAMBERT COMPANY (US) | 1986-07-16 | — | — | EP | disclosed |
| EP-0026000-B1 | SPIRO COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Takeda Chemical Industries, Ltd. (JP) | 1983-05-11 | — | — | EP | disclosed |
| EP-0026000-A1 | Spiro compounds, process for their preparation and pharmaceutical compositions containing them | Takeda Chemical Industries, Ltd. (JP) | 1981-04-01 | — | — | EP | disclosed |
| US-3953595-A | Substituted benzoic acid hypolipemic agents | PFIZER INC. (US) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119237-A1 | Non-malignant disease treatment with Ras antagonists | RSU1, KSR1, KRAS | CA1 3526/4885CA2 4378/4885P2RX1 4669/4885 |
| US-10399986-B2 | Inhibitors of leukotriene A4 hydrolase | LTA4H, LTC4S, LTB4R | CA1 2810/4885CA2 3422/4885P2RX1 861/4885 |
| US-20180127424-A1 | INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTC4S, LTB4R | CA1 2810/4885CA2 3422/4885P2RX1 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.